When.com Web Search

  1. Ads

    related to: lipitor vs crestor reviews

Search results

  1. Results From The WOW.Com Content Network
  2. AstraZeneca's Crestor Fails to Best Lipitor in Study - AOL

    www.aol.com/news/2011-09-02-astrazenecas-crestor...

    AstraZeneca (NYS: AZN) just lost a potential marketing edge for Crestor. In trial results announced today, the statin drug failed to best Lipitor at clearing clogged arteries, at least in a ...

  3. Rosuvastatin - Wikipedia

    en.wikipedia.org/wiki/Rosuvastatin

    Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. [6] It is recommended to be used together with dietary changes, exercise, and weight loss. [ 6 ]

  4. AZ's Crestor Scored Points, but Didn't Beat Lipitor - AOL

    www.aol.com/news/2011-11-15-azs-crestor-scored...

    AstraZeneca's (NYS: ANZ) press release on the SATURN trial is an object lesson in how to spin a study that didn't turn out as expected: Focus on the positive. The company announced SATURN showed ...

  5. When a Good Idea Goes Bad - AOL

    www.aol.com/news/2011-09-02-when-a-good-idea...

    Give AstraZeneca (NYS: AZN) credit for attempting to differentiate Crestor as the cholesterol drug market is about to get flooded with generic versions of Pfizer's (NYS: PFE) top-selling Lipitor.

  6. Statin - Wikipedia

    en.wikipedia.org/wiki/Statin

    A 2013 Cochrane review found a decrease in risk of death and other poor outcomes without any evidence of harm. [4] For every 138 people treated for 5 years, one fewer dies; for every 49 treated, one fewer has an episode of heart disease. [11] A 2011 review reached similar conclusions, [26] and a 2012 review found benefits in both women and men ...

  7. JUPITER trial - Wikipedia

    en.wikipedia.org/wiki/JUPITER_trial

    JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).